Can cholestyramine (Questran) be added to a patient with Clostridioides difficile infection who is being treated with oral vancomycin for diarrhea?

Do Not Add Cholestyramine (Questran) to Vancomycin for Active C. difficile Infection

Cholestyramine should NOT be used concurrently with oral vancomycin during active C. difficile infection treatment, as it binds vancomycin and reduces its antibacterial activity 1.

Why This Combination Is Contraindicated

The 2026 AGA Clinical Practice Update explicitly states that cholestyramine and other bile acid-binding agents should not be used as monotherapy or concurrently with oral vancomycin or fidaxomicin 1. This recommendation is based on the pharmacologic interaction between these agents:

• Cholestyramine is an anion-exchange resin that binds vancomycin in the gut, significantly reducing the antibacterial activity of vancomycin 2
• While bound vancomycin retains some initial antibacterial activity, the degree of inactivation increases with duration of contact between the two drugs 2
• When vancomycin-cholestyramine suspensions are tested, the supernatant shows markedly reduced antibacterial activity after centrifugation, confirming significant drug binding 2

When Cholestyramine Might Be Considered

Cholestyramine has a very limited role in C. difficile management:

• Only after multiple recurrences (≥3 episodes) as an adjunct to tapered-pulsed vancomycin regimens 3, 4
• Never during active treatment with standard-dose vancomycin
• Historical case reports showed benefit in relapsing disease, but this was in the context of binding C. difficile toxins, not as concurrent therapy with vancomycin 5

Current Treatment Algorithm for Your Patient

For a patient with active C. difficile infection on vancomycin:

1. Continue vancomycin 125 mg four times daily for 10 days as standard therapy 6
2. Do not add cholestyramine during this treatment period
3. Monitor for treatment response - diarrhea should improve within 3-5 days
4. If this is a first recurrence, consider switching to fidaxomicin or tapered-pulsed vancomycin after completing the current course 6
5. If multiple recurrences occur, consider fecal microbiota-based therapy rather than adding cholestyramine 1

Important Clinical Pitfall

The common misconception is that cholestyramine helps by binding C. difficile toxins during active infection. While theoretically appealing, the drug interaction with vancomycin outweighs any potential toxin-binding benefit, and current guidelines strongly advise against concurrent use 1.

For symptomatic diarrhea management after infection resolution, psyllium fiber can be used to bulk stools, but only after completing antibiotic therapy 1.